{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:30:11Z","timestamp":1764700211882},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,3,12]],"date-time":"2008-03-12T00:00:00Z","timestamp":1205280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s00280-008-0700-3","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T04:42:49Z","timestamp":1205210569000},"page":"1075-1083","source":"Crossref","is-referenced-by-count":12,"title":["Cisplatin plus weekly CPT-11\/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms"],"prefix":"10.1007","volume":"62","author":[{"given":"Albert","family":"Font","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Maurel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miquel","family":"Taron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enric","family":"Carcereny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Guix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Fern\u00e1ndez-Llamazares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,12]]},"reference":[{"key":"700_CR1","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1200\/JCO.2005.17.376","volume":"23","author":"JA Ajani","year":"2005","unstructured":"Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Filho SC, Maijlis A, Assadourian S, Van Cutsem E (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660\u20135667","journal-title":"J Clin Oncol"},{"key":"700_CR2","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Yoshinori Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921\u20136926","journal-title":"Cancer Res"},{"key":"700_CR3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.1999.17.1.319","volume":"17","author":"N Boku","year":"1999","unstructured":"Boku N, Ohtsu A, Shimada Y, Narikazu Boku, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319\u2013323","journal-title":"J Clin Oncol"},{"issue":"7","key":"700_CR4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1101\/gad.13.7.768","volume":"13","author":"WL Laat De","year":"1999","unstructured":"De Laat WL, Jaspers NG, Hoeijmakers JH (1999) Molecular mechanism of nucleotide excision repair. Genes Dev 13(7):768\u2013785","journal-title":"Genes Dev"},{"key":"700_CR5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/annonc\/mdj135","volume":"17","author":"R las Pe\u00f1as De","year":"2006","unstructured":"De las Pe\u00f1as R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, S\u00e1nchez JJ, Rosell R (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin\/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17:668\u2013675","journal-title":"Ann Oncol"},{"key":"700_CR6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0169-5002(02)00081-8","volume":"37","author":"A Font","year":"2002","unstructured":"Font A, Sanchez JM, Rosell R, Taron M, Martinez E, Guillot M, Manzano JL, Margeli M, Barnadas A, Abad A (2002) Phase I study of weekly CPT-11(irinotecan)\/docetaxel in patients with advanced solid tumors. Lung Cancer 37:213\u2013218","journal-title":"Lung Cancer"},{"key":"700_CR7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/A:1026251202137","volume":"21","author":"A Font","year":"2003","unstructured":"Font A, Sanchez JM, Taron M, Martinez-Balibrea E, Sanchez JJ, Manzano JL, Margel\u00ed M, Richardet M, Barnadas A, Abad A, Rosell R (2003) Weekly regimen of irinotecan\/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 21:435\u2013443","journal-title":"Invest New Drugs"},{"key":"700_CR8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/mol.62.3.608","volume":"62","author":"JF Gagne","year":"2002","unstructured":"Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C (2002) Common human UGT1A1 polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxicamptothecin (SN-38). Mol Pharmacol 62:608\u2013617","journal-title":"Mol Pharmacol"},{"key":"700_CR9","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-05-2130","volume":"12","author":"JF Gagnon","year":"2006","unstructured":"Gagnon JF, Bernard O, Villeneuve L, T\u00eatu B, Guillemette C (2006) Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 12:1850\u20131858","journal-title":"Clin Cancer Res"},{"key":"700_CR10","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.2004.08.067","volume":"22","author":"S Gurubhagavatula","year":"2004","unstructured":"Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594\u20132601","journal-title":"J Clin Oncol"},{"key":"700_CR11","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1999.17.10.3270","volume":"17","author":"DH Ilson","year":"1999","unstructured":"Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O\u00b4Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen DP (1999) Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17:3270\u20133275","journal-title":"J Clin Oncol"},{"key":"700_CR12","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","volume":"22","author":"F Innocenti","year":"2004","unstructured":"Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382\u20131388","journal-title":"J Clin Oncol"},{"key":"700_CR13","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdh319","volume":"15","author":"D Isla","year":"2004","unstructured":"Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nu\u00f1ez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A, Lianes P (2004) Single nucleotde polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194\u20131203","journal-title":"Ann Oncol"},{"key":"700_CR14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0009-9236(99)70078-0","volume":"65","author":"L Iyer","year":"1999","unstructured":"Iyer L, Hall D, Das S et al. (1999) Phenotype-genotype correlation of in-vitro SN-38 (active metabolite of irinotecan) and bilirubin glucoronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576\u2013582","journal-title":"Clin Pharmacol Ther"},{"key":"700_CR15","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6602042","volume":"91","author":"E Marcuello","year":"2004","unstructured":"Marcuello E, Alt\u00e9s A, Menoyo A, Del Rio E, G\u00f3mez-Pardo M, Baiget M (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer Br J Cancer 91:678\u2013682","journal-title":"Br J Cancer"},{"key":"700_CR16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/carcin\/22.9.1437","volume":"22","author":"G Matullo","year":"2001","unstructured":"Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E, Krogh V, Munnia A, Tumino R, Polidoro S, Piazza A,Vineis P (2001) XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22:1437\u20131445","journal-title":"Carcinogenesis"},{"key":"700_CR17","first-page":"8654","volume":"61","author":"DJ Park","year":"2001","unstructured":"Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ (2001) A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654\u20138658","journal-title":"Cancer Res"},{"key":"700_CR18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74\u2013108","journal-title":"CA Cancer J Clin"},{"key":"700_CR19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1008328501128","volume":"12","author":"K Ridwelski","year":"2001","unstructured":"Ridwelski K, Gebauer T, Fahlke J, Kr\u00f6ning H, Kettner E, Meyer F, Eichelmann K, Lippert H (2001) Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12:47\u201351","journal-title":"Ann Oncol"},{"key":"700_CR20","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2002.08.105","volume":"20","author":"P Ross","year":"2002","unstructured":"Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickisk T, Lofts F, Norman A (2002) Prospective randomized trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996\u20132004","journal-title":"J Clin Oncol"},{"key":"700_CR21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1008342013224","volume":"11","author":"AD Roth","year":"2000","unstructured":"Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute Of Oncology (EIO). Ann Oncol 11:301\u2013306","journal-title":"Ann Oncol"},{"key":"700_CR22","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1200\/JCO.2005.04.8322","volume":"24","author":"A Ruzzo","year":"2006","unstructured":"Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, Bisonni R, Canestrari E, Ficarelli R, Menichetti ET, Mari D, Testa E, Silva R, Vincenzi B, Giordani P, Cascinu S, Giustini L, Tonini G, Magnani M (2006) Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24:1883\u20131891","journal-title":"J Clin Oncol"},{"key":"700_CR23","doi-asserted-by":"crossref","unstructured":"Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F, Falcone A, Canestrari E, Tonini G, Mari D, Lippe P, Pizzagalli F, Schiavon G, Alessandroni P, Giustini L, Maltese P, Testa E, Menichetti ET, Magnani M (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J. doi:10.1038\/sj.tpj.6500463","DOI":"10.1038\/sj.tpj.6500463"},{"key":"700_CR24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.1997.15.3.921","volume":"15","author":"K Shirao","year":"1997","unstructured":"Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama T, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda Y, Muro K, Yoshida S (1997) Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921\u2013927","journal-title":"J Clin Oncol"},{"key":"700_CR25","first-page":"1354","volume":"61","author":"MR Spitz","year":"2001","unstructured":"Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, Guo Z, Lei L, Mohrenweiser H, Wei Q (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354\u20131357","journal-title":"Cancer Res"},{"key":"700_CR26","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2005.05.5400","volume":"24","author":"G Toffoli","year":"2006","unstructured":"Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D\u00a8Andrea M, Pasetto LM, Pessa S, Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, Bonura S, Boccalon M, Biason P, Frustaci S (2006) The role of UGT1A*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061\u20133068","journal-title":"J Clin Oncol"},{"key":"700_CR27","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"Cutsem Van","year":"2006","unstructured":"Van Cutsem, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24:4991\u20134997","journal-title":"J Clin Oncol"},{"key":"700_CR28","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.2000.18.14.2648","volume":"18","author":"U Vanhoefer","year":"2000","unstructured":"Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Dos Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreor ML, Baron B, Wils JA (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648\u20132657","journal-title":"J Clin Oncol"},{"key":"700_CR29","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903\u20132909","journal-title":"J Clin Oncol"},{"key":"700_CR30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0959-8049(97)86090-X","volume":"15","author":"A Webb","year":"1997","unstructured":"Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK , Hughes M, Mansi J, Findlay M, Hill A, Oates J , Nicolson M, Hickish T, O\u2019Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261\u2013267","journal-title":"J Clin Oncol"},{"key":"700_CR31","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/annonc\/mdh422","volume":"15","author":"SS W\u00f6hrer","year":"2004","unstructured":"W\u00f6hrer SS, Raderer, Hejna M. (2004) Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15:1585\u20131595","journal-title":"Ann Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0700-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-008-0700-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0700-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:06:51Z","timestamp":1559023611000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0700-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0700-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,12]]}}}